Incretin-based therapy including GLP-1 RAs as well as GIP and GLP-1 dual-RAs may exacerbate the severity of hypoglycemic episodes from an existing insulinoma, as insulinoma commonly overexpresses GIP and GLP-1 receptors. This evidence concerns the gene GIP and pancreatic insulinoma.